Company news

COSCIENS Biopharma Inc. news in 2013

COSCIENS Biopharma Inc.'s news releases, calls and decks from 2013, newest first.

View company

Aeterna Zentaris Announces Closing of US$15.1 Million Public Offering of Common Shares and Warrants

November 25, 2013

Aeterna Zentaris Announces Pricing of US$15.1 Million Public Offering of Common Shares and Warrants

November 20, 2013

Aeterna Zentaris Reports Third Quarter 2013 Financial and Operating Results

November 5, 2013

Aeterna Zentaris Appoints Chief Commercial Officer, Reaffirming New Company Vision

November 1, 2013

Aeterna Zentaris to Announce Third Quarter 2013 Financial and Operating Results on November 5, 2013

October 29, 2013

Aeterna Zentaris Completes Successful Transfer of Cetrotide® Manufacturing Rights to Merck KGaA

October 1, 2013

Aeterna Zentaris Announces Listing Transfer to NASDAQ Capital Market

August 28, 2013

Aeterna Zentaris Reports Second Quarter 2013 Financial and Operating Results

August 8, 2013

Aeterna Zentaris to Present at Upcoming Canaccord Genuity Global Growth Conference in Boston

August 7, 2013

Aeterna Zentaris to Announce Second Quarter 2013 Financial and Operating Results on August 8, 2013

August 1, 2013

Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin (AEZS-108)

July 31, 2013

Aeterna Zentaris Completes $7.8 Million Registered Direct Offering

July 30, 2013

Aeterna Zentaris to Raise US$7.8 Million in Registered Direct Offering

July 25, 2013

Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO

June 3, 2013

Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting

May 23, 2013

Aeterna Zentaris Announces "At-the-Market" Issuance Program

May 21, 2013

Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

May 8, 2013

Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results

May 7, 2013

Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013

May 1, 2013

Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013

April 23, 2013

Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA

April 17, 2013

David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc.

April 15, 2013

Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting

April 10, 2013

Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting

April 3, 2013

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results

March 21, 2013

Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference

March 13, 2013

Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013

March 12, 2013

Aeterna Zentaris: First Patient Treated for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer

February 20, 2013

Decks in 2013